# BLUDIGO
> **NDA216264** · New Drug Application · Sponsor: PROVEPHARM SAS · Approved 2022-07-08
## Drug
- **FDA Application Number:** NDA216264
- **Application type:** New Drug Application
- **Brand name:** BLUDIGO
- **Generic name:** INDIGOTINDISULFONATE SODIUM
- **Active ingredients:** INDIGOTINDISULFONATE SODIUM
- **Dosage form:** SOLUTION
- **Route:** INTRAVENOUS
- **Marketing status:** Prescription
- **Sponsor:** PROVEPHARM SAS
- **Manufacturer:** Sagent Pharmaceuticals
- **First approval:** 2022-07-08
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216264)
---
*MORVS · CC0 1.0*